{"schema_version":"secwatch.filing_event.v1","accession":"0001651944-24-000044","form_type":"8-K","ticker":null,"cik":"0001651944","company_name":"DermTech, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.436790+00:00","generated_at":"2026-06-02T00:56:36.128158+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"DermTech Q1 revenue up 11% to $3.8M; net loss narrows to $20M","bullets":["Test revenue $3.7M (+7% YoY); billable sample volume ~15,360 (-14% YoY).","Net loss $20.0M ($0.58/share) vs. $31.3M ($1.02/share) in Q1 2023.","Test gross margin improved to 16% from -11% YoY on 19% lower cost of test revenue.","Sales & marketing expenses down 49% to $7.8M; G&A down 15% to $10.1M.","Cash, equivalents and marketable securities $42.4M at March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001651944-24-000044","json":"https://secwatch.observer/filing/0001651944-24-000044.json","markdown":"https://secwatch.observer/filing/0001651944-24-000044.md","text":"https://secwatch.observer/filing/0001651944-24-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/0001651944-24-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/dmtk-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:56:36.128158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac7e3b84340589b793736a43895715917cc9a262","claim":"DermTech, Inc. reported the quarter ended March 31, 2024 results: revenue $3.8 million, net income Net loss was $20.0 million, EPS ($0.58) per share.","evidence_excerpt":"First-Quarter 2024 Financial Results • Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. • Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. • Total revenue was $3.8 million, an 11 percent increase from the first quarter of 2023, driven by higher test revenue. • Cost of test revenue was $3.1 million, a 19 percent decrease from the first quarter of 2023, yielding a test gross margin of 16 percent, compared to negative 11 percent for the first quarter of 2023. Cost of test revenue decreased primarily because of lower employee-related costs. • Sales and marketing expenses were $7.8 million, a 49 percent decrease from the first quarter of 2023. The decrease was primarily attributable to lower employee-related and marketing expenditures. • Research and development expenses were $3.3 million, a 26 percent decrease from the first quarter of 2023, largely due to lower employee-","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651944/000165194424000044/0001651944-24-000044-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"Net loss was $20.0 million"},{"label":"EPS","value":"($0.58) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}